Indivior Pharmaceuticals, Inc. Adjustments For Decrease Increase In Trade Account Receivable
Indivior Pharmaceuticals, Inc. (SUPN) reported Adjustments For Decrease Increase In Trade Account Receivable of -$33.00 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-06.
Discontinued › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable · last filed 2024-03-06
| Period end | Adjustments For Decrease Increase In Trade Account Receivable 12 month |
|---|---|
| 2023-12-31 | -$33.00M 20-F · filed 2024-03-06 |
| 2022-12-31 | -$21.00M 20-F · filed 2024-03-06 |
| 2021-12-31 | -$25.00M 20-F · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |